Want to see ACXP full AI Analyst Report?
Acurx Pharmaceuticals (ACXP) Stock Statistics & Valuation Metrics
Total Valuation
Acurx Pharmaceuticals has a market cap or net worth of $5.78M. The enterprise value is -$4.05M.
- Market Cap
- $5.78M
- Enterprise Value
- -$4.05M
Share Statistics
Acurx Pharmaceuticals has 5,559,405 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 5,559,405
- Owned by Insiders
- 42.84%
- Owned by Institutions
- 1.84%
Financial Efficiency
Acurx Pharmaceuticals’s return on equity (ROE) is -1.51 and return on invested capital (ROIC) is -153.59%.
- Return on Equity (ROE)
- -1.51
- Return on Assets (ROA)
- -1.04
- Return on Invested Capital (ROIC)
- -153.59%
- Return on Capital Employed (ROCE)
- -1.54
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.99M
- Employee Count
- 4
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Acurx Pharmaceuticals is -0.29. Acurx Pharmaceuticals’s PEG ratio is -0.00.
- PE Ratio
- -0.29
- PS Ratio
- 0.00
- PB Ratio
- 0.54
- Price to FCF
- -0.94
- Price to Operating Cash Flow
- -0.72
- PEG Ratio
- -0.00
Income Statement
In the last 12 months, Acurx Pharmaceuticals had revenue of 0 and earned -7.97M in profits. Earnings per share was -5.32.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -8.09M
- Pretax Income
- -7.97M
- Net Income
- -7.97M
- EBITDA
- -7.97M
- Earnings Per Share (EPS)
- -5.32
Cash Flow
In the last 12 months, operating cash flow was -6.18M and capital expenditures 0, giving a free cash flow of -6.18M billion.
- Operating Cash Flow
- -6.18M
- Free Cash Flow
- -6.18M
- Free Cash Flow per Share
- -1.45
Dividends & Yields
Acurx Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -106.94%
- Earnings Yield
- -169.44%
Stock Price Statistics
- Beta
- -0.47
- 52-Week Price Change
- -79.61%
- 50-Day Moving Average
- 1.30
- 200-Day Moving Average
- 1.97
- Relative Strength Index (RSI)
- 26.59
- Average Volume (3m)
- 120.00K
Important Dates
Acurx Pharmaceuticals upcoming earnings date is Nov 12, 2026, Before Open (Not Confirmed).
- Last Earnings Date
- Aug 14, 2026
- Next Earnings Date
- Nov 12, 2026
- Ex-Dividend Date
- ―
Financial Position
Acurx Pharmaceuticals as a current ratio of 3.18, with Debt / Equity ratio of 0.00%
- Current Ratio
- 3.18
- Quick Ratio
- 3.18
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.95
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Acurx Pharmaceuticals has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Acurx Pharmaceuticals EV to EBITDA ratio is 0.64, with an EV/FCF ratio of 0.79.
- EV to Sales
- 0.00
- EV to EBITDA
- 0.64
- EV to Free Cash Flow
- 0.79
- EV to Operating Cash Flow
- 0.79
Balance Sheet
Acurx Pharmaceuticals has $10.66M in cash and marketable securities with $0.00 in debt, giving a net cash position of $10.66M billion.
- Cash & Marketable Securities
- $10.66M
- Total Debt
- $0.00
- Net Cash
- $10.66M
- Net Cash Per Share
- $1.92
- Tangible Book Value Per Share
- $1.91
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Acurx Pharmaceuticals is $17.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $17.00
- Price Target Upside
- 1534.62% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 3
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 71.66%
Scores
- Smart Score
- ―
- AI Score
- 44